The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy

References

• Abou-Jawde R, Choueiri T, Alemany C, Mekhail T. 2003. An overview of targeted treatments in cancer. Clin Ther. 25:2121–2137.
   PubMed Web of Science ®Google Scholar
• Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. 2001. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61:4750–4755.
   PubMed Web of Science ®Google Scholar
• Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. 2012. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012:980250.
   PubMed Web of Science ®Google Scholar
• Ajima K, Murakami T, Mizoguchi Y, Tsuchida K, Ichihashi T, Iijima S, Yudasaka M. 2008. Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. Acs Nano. 2:2057–2064.
   PubMed Web of Science ®Google Scholar
• Allen TM. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2:750–763.
   PubMed Web of Science ®Google Scholar
• Allen TM. 1994. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 15:215–220.
   PubMed Web of Science ®Google Scholar
• Amato G. 2010. Silica-encapsulated efficient and stable Si quantum dots with high biocompatibility. Nanoscale Res Lett. 5:1156–1160.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical Research. 25:2097–2116.
   PubMed Web of Science ®Google Scholar
• Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. 2007. Magnetic nanoparticles for drug delivery. Nano Today. 2:22–32.
   Web of Science ®Google Scholar
• Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, Kohli K. 2011. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol. 63:141–163.
   PubMed Web of Science ®Google Scholar
• Benita S. 2005. Microencapsulation: methods and industrial applications. CRC Press.
   Google Scholar
• Bradbury AR, Sidhu S, D bel S, McCafferty J. 2011. Beyond natural antibodies: the power of in vitro display technologies. Nature biotechnology, 29, 245–254.
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. 2012. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 64:206–212.
   Web of Science ®Google Scholar
• Bray F, Møller B. 2006. Predicting the future burden of cancer. Nat Rev Cancer. 6:63–74.
   PubMed Web of Science ®Google Scholar
• Brennan FR, Shaw L, Wing MG, Robinson C. 2004. Preclinical safety testing of biotechnology-derived pharmaceuticals. Mol Biotechnol. 27:59–74.
   PubMed Web of Science ®Google Scholar
• Cabral H, Kataoka K. 2014. Progress of drug-loaded polymeric micelles into clinical studies. Journal of Controlled Release, 190, 465–476.
   PubMed Web of Science ®Google Scholar
• Caminade A-M, Laurent R, Majoral J-P. 2005. Characterization of dendrimers. Adv Drug Deliv Rev. 57:2130–2146.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature. 407:249–257.
   PubMed Web of Science ®Google Scholar
• Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 1:118–129.
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 14:1310–1316.
   PubMed Web of Science ®Google Scholar
• Cole AJ, Yang VC, David AE. 2011. Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol. 29:323–332.
   PubMed Web of Science ®Google Scholar
• Conti M, Tazzari V, Baccini C, Pertici G, Serino LP, De Giorgi U. 2006. Anticancer drug delivery with nanoparticles. In Vivo. 20:697–701.
   Google Scholar
• Couvreur P, Vauthier C. 2006. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 23:1417–1450.
   PubMed Web of Science ®Google Scholar
• Daemen T, Hofstede G, Ten Kate MT, Bakker‐Woudenberg IA, Scherphof GL. 1995. Liposomal doxorubicin‐induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer. 61:716–721.
   PubMed Web of Science ®Google Scholar
• Davis ME, Shin DM. 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 7:771–782.
   PubMed Web of Science ®Google Scholar
• des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 116:1–27.
   PubMed Web of Science ®Google Scholar
• Di Pasqua AJ, Wallner S, Kerwood DJ, Dabrowiak JC. 2009. Adsorption of the PtII anticancer drug carboplatin by mesoporous silica. Chem Biodivers. 6:1343–1349.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. 2007. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2:469–478.
   PubMed Web of Science ®Google Scholar
• Dou S, Yang XZ, Xiong MH, Sun CY, Yao YD, Zhu YH, Wang J. 2014. ScFv‐decorated PEG‐PLA‐based nanoparticles for enhanced siRNA delivery to Her2 + breast cancer. Adv Healthc Mater. 3: 1792–1803.
   PubMed Web of Science ®Google Scholar
• Douer D, Estey E, Santillana S, Bennett JM, Lopez-Bernstein G, Boehm K, Williams T. 2001. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-transretinoic acid. Blood. 97:73–80.
   PubMed Web of Science ®Google Scholar
• Echeverría JC, Estella J, Barbería V, Musgo J, Garrido JJ. 2010. Synthesis and characterization of ultramicroporous silica xerogels. J Non-Cryst Solids. 356:378–382.
   Web of Science ®Google Scholar
• Farokhzad OC, Langer R. 2009. Impact of nanotechnology on drug delivery. ACS Nano. 3:16–20.
   PubMed Web of Science ®Google Scholar
• Ferrari M. 2005. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 5:161–171.
   PubMed Web of Science ®Google Scholar
• Fidalgo A, Lopez TM, Ilharco LM. 2009. Wet sol–gel silica matrices as delivery devices for phenytoin. J Sol-Gel Sci Technol. 49:320–328.
   Web of Science ®Google Scholar
• Foldvari M, Bagonluri M. 2008. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine NBM. 4:183–200.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CC, Dorland R, Van Kregten J, Manca F, Vugts DJ, et al. 2014. Pharmacokinetics, brain delivery, and efficacy in brain tumorbearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PloS one. 9:e82331.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, van de Winkel JG. 2003. Renaissance of cancer therapeutic antibodies. Drug Discov Today. 8:503–510.
   PubMed Web of Science ®Google Scholar
• Grassi-Schultheiss P, Heller F, Dobson J. 1997. Analysis of magnetic material in the human heart, spleen and liver. Biometals. 10:351–355.
   PubMed Web of Science ®Google Scholar
• Guo S, Huang L. 2013. Nanoparticles containing insoluble drug for cancer therapy. Biotechnology advances.
   Web of Science ®Google Scholar
• Hajdu SI. 2011. A note from history: landmarks in history of cancer, part 1. Cancer. 117:1097–1102.
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. 2008. Nanoparticles for drug delivery in cancer treatment. In: Urologic Oncology: Seminars and original investigations. Elsevier: 57–64.
   Google Scholar
• Holliger P, Hudson PJ. 2005. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 23:1126–1136.
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Aryal S, Zhang L. 2010. Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeu Deliv. 1:323–334.
   PubMedGoogle Scholar
• Hudson PJ. 1998. Recombinant antibody fragments. Curr Opin Biotechnol. 9:395–402.
   PubMed Web of Science ®Google Scholar
• Jain S, Hirst D, O’Sullivan J. 2014. Gold nanoparticles as novel agents for cancer therapy.
   Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin. 58:71–96.
   PubMed Web of Science ®Google Scholar
• Jia G, Wang H, Yan L, Wang X, Pei R, Yan T, Zhao Y, Guo X. 2005. Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ Sci Technol. 39:1378–1383.
   PubMed Web of Science ®Google Scholar
• Kato Y, Seita T, Kuwabara T, Sugiyama Y. 1996. Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: use of RME as a drug delivery system. J Controlled Release. 39:191–200.
   Web of Science ®Google Scholar
• Köhler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495–497.
   PubMed Web of Science ®Google Scholar
• Kovacevic A, Savic S, Vuleta G, Müller R, Keck C. 2011. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC). effects on size, physical stability and particle matrix structure. Int J Pharm. 406:163–172.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. 2010. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces. 75:1–18.
   PubMed Web of Science ®Google Scholar
• Kyung OY, Grabinski CM, Schrand AM, Murdock RC, Wang W, Gu B, et al. 2009. Toxicity of amorphous silica nanoparticles in mouse keratinocytes. J Nanopart Res. 11:15–24.
   Web of Science ®Google Scholar
• Leamon CP, Reddy JA. 2004. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 56:1127–1141.
   PubMed Web of Science ®Google Scholar
• Li Z, Su K, Cheng B, Deng Y. 2010. Organically modified MCM-type material preparation and its usage in controlled amoxicillin delivery. J Colloid Interface Sci. 342:607–613.
   PubMed Web of Science ®Google Scholar
• Li C, Wallace S. 2008. Polymer-drug conjugates: recent development in clinical oncology. Advanced drug delivery reviews, 60, 886–898.
   PubMed Web of Science ®Google Scholar
• Lin W, Huang Y-W, Zhou X-D, Ma Y. 2006. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 217:252–259.
   PubMed Web of Science ®Google Scholar
• Liu X, Sun J. 2010. Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways. Biomaterials. 31:8198–8209.
   PubMed Web of Science ®Google Scholar
• Lu R-M, Chang Y-L, Chen M-S, Wu H-C. 2011. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 32:3265–3274.
   PubMed Web of Science ®Google Scholar
• Luo X, Matranga C, Tan S, Alba N, Cui XT. 2011. Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone. Biomaterials. 32:6316–6323.
   PubMed Web of Science ®Google Scholar
• Maeda H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 41:189–207.
   PubMedGoogle Scholar
• Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. 2012. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet oncol. 13:1234–1241.
   PubMed Web of Science ®Google Scholar
• Manchester M, Singh P. 2006. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev. 58:1505–1522.
   PubMed Web of Science ®Google Scholar
• Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, et al. 2003. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63:4062–4066.
   PubMed Web of Science ®Google Scholar
• Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K. 2006. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett. 235:298–308.
   PubMed Web of Science ®Google Scholar
• Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ. 2013. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical Cancer Research, 19, 347–356.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. 2004. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 15:517–525.
   PubMed Web of Science ®Google Scholar
• Maynard J, Georgiou G. 2000. Antibody engineering. Annu Rev Biomed Eng. 2:339–376.
   PubMed Web of Science ®Google Scholar
• Mellet CO, Fern ndez JMG, Benito JM. 2011. Cyclodextrin-based gene delivery systems. Chemical Society Reviews, 40, 1586–1608.
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. 2009. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. International journal of nanomedicine, 4, 99.
   PubMed Web of Science ®Google Scholar
• Miller A, Hoogstraten B, Staquet M, Winkler A. 1981. Reporting Results of cancer treatment. Cancer. 47:207–214.
   PubMed Web of Science ®Google Scholar
• Monnier PP, Vigouroux RJ, Tassew NG. 2013. In vivo applications of single chain Fv (variable domain)(scFv) fragments. Antibodies. 2:193–208.
   Google Scholar
• Murakami T, Sawada H, Tamura G, Yudasaka M, Iijima S, Tsuchida K. 2008. Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomedicine (Lond). 3:453–63.
   PubMed Web of Science ®Google Scholar
• Naqvi S, Samim M, Abdin M, Ahmed FJ, Maitra A, Prashant C, Dinda AK. 2010. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine. 5:983–989.
   PubMed Web of Science ®Google Scholar
• Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, et al. 2005. Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis. Biotechnol prog. 21:221–232.
   PubMed Web of Science ®Google Scholar
• Nevozhay D, Kańska U, Budzyńska R, Boratyński J. 2006. [Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases]. Postepy Hig Med Dosw (Online). 61:350–360.
   Google Scholar
• Nomura T, Saikawa A, Morita S, Yamashita F, Honda K, Takakura Y, Hashida M. 1998. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. J Control Release. 52:239–252.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, et al. 2013. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome–negative acute lymphoblastic leukemia. Journal of clinical oncology, 31, 676–683.
   PubMed Web of Science ®Google Scholar
• Owens DE III, Peppas NA. 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 307:93–102.
   PubMed Web of Science ®Google Scholar
• Park E-J, Park K. 2009. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol Lett. 184:18–25.
   PubMed Web of Science ®Google Scholar
• Park K, Lee S, Kang E, Kim K, Choi K, Kwon IC. 2009. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv Funct Mater. 19:1553–1566.
   Web of Science ®Google Scholar
• Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. 2006. Immunotoxin therapy of cancer. Nat Rev Cancer. 6:559–565.
   PubMed Web of Science ®Google Scholar
• Patri AK, Kukowska-Latallo JF, Baker Jr. 2005. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev. 57:2203–2214.
   PubMed Web of Science ®Google Scholar
• Pavlinkova G, Colcher D, Booth BJ, Goel A, Wittel UA, Batra SK. 2001. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti‐tag‐72 single‐chain Fvs. Int J Cancer. 94:717–726.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. 2007a. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751–760.
   PubMed Web of Science ®Google Scholar
• Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. 2007b. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci. 104:4095–4100.
   PubMed Web of Science ®Google Scholar
• Pelicano H, Martin D, Xu R, Huang P. 2006. Glycolysis inhibition for anticancer treatment. Oncogene. 25:4633–4646.
   PubMed Web of Science ®Google Scholar
• Perez E. 2005. American Pharmaceutical Partners announces presentation of Abraxane survival data. In: 22nd annual Miami Breast Cancer Conference; Miami: FL.
   Google Scholar
• Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, et al. 2009. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol. 27:6052–6069.
   PubMed Web of Science ®Google Scholar
• Pillai G, Ceballos-Coronel ML. 2013. Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Medicine, 1, 2050312113513759.
   PubMedGoogle Scholar
• Popovici R, Seftel E, Mihai G, Popovici E, Voicu V. 2011. Controlled drug delivery system based on ordered mesoporous silica matrices of captopril as angiotensin‐converting enzyme inhibitor drug. J Pharm Sci. 100:704–714.
   PubMed Web of Science ®Google Scholar
• Pucca MB, Bertolini TB, Barbosa JE, Galina SVR, Porto GS. 2011. Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. Braz J Pharm Sci. 47:31–38.
   Web of Science ®Google Scholar
• Qian ZM, Li H, Sun H, Ho K. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 54:561–587.
   PubMed Web of Science ®Google Scholar
• Riggio C, Pagni E, Raffa V, Cuschieri A. 2011. Nano-oncology: clinical application for cancer therapy and future perspectives. Journal of Nanomaterials, 2011, 17.
   Web of Science ®Google Scholar
• Rivera, E. 2003. Liposomal anthracyclines in metastatic breast cancer: clinical update. The oncologist, 8, 3–9.
   PubMed Web of Science ®Google Scholar
• Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. 2005. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 65:1471–1478.
   PubMed Web of Science ®Google Scholar
• Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, et al. 2004. Targeted therapies for cancer 2004. Am J Clin Pathol. 122: 598–609.
   PubMed Web of Science ®Google Scholar
• Santos Giuberti CD, de Oliveira Reis EC, Ribeiro Rocha TG, Leite EA, Lacerda RG, Ramaldes GA, de Oliveira MC. 2011. Study of the pilot production process of long-circulating and pH-sensitive liposomes containing cisplatin. J Liposome Res. 21:60–69.
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. 2002. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62:7190–7194.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Matsuno K, Yamagata N, Fujisawa T, Wasserman E, Sutherland W, Sharma S, Phan A. 2009. Abstract C36: MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics. Molecular Cancer Therapeutics, 8, C36–C36.
   PubMed Web of Science ®Google Scholar
• Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, et al. 2013. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 21:1096–1103.
   PubMed Web of Science ®Google Scholar
• Shenoy DB, Amiji MM. 2005. Poly (ethylene oxide)-modified poly (ɛ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharma. 293:261–270.
   PubMed Web of Science ®Google Scholar
• Shiba K, Yudasaka M, Iijima S. 2006. [Carbon nanohorns as a novel drug carrier]. Nihon Rinsho. 64:239–246.
   PubMedGoogle Scholar
• Sidhu SS, Fellouse FA. 2006. Synthetic therapeutic antibodies. Nature chemical biology, 2, 682–688.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS. et al. 2010. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood, 115, 1351–1353.
   PubMed Web of Science ®Google Scholar
• Singh P, Destito G, Schneemann A, Manchester M. 2006. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology. 4:1–11.
   PubMed Web of Science ®Google Scholar
• Singh P, Gupta U, Asthana A, Jain NK. 2008. Folate and folate− PEG− PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem. 19:2239–2252.
   PubMed Web of Science ®Google Scholar
• Sinha R, Kim GJ, Nie S, Shin DM. 2006. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 5:1909–1917.
   PubMed Web of Science ®Google Scholar
• Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, et al. 1998. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. Journal of Clinical Oncology, 16, 683–691.
   PubMed Web of Science ®Google Scholar
• Sun C, Lee JS, Zhang M. 2008. Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Deliv Rev. 60:1252–1265.
   PubMed Web of Science ®Google Scholar
• Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, et al. 2003. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 44:1962–1969.
   PubMed Web of Science ®Google Scholar
• Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE. 2006. Targeted nanoparticles for detecting and treating cancer. Drug Develop Res. 67:70–93.
   Web of Science ®Google Scholar
• Suzawa T, Nagamura S, Saito H, Ohta S, Hanai N, Kanazawa J, et al. 2002. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly (ethylene glycol)-based cleavable linker. J Controlled Release. 79:229–242.
   PubMed Web of Science ®Google Scholar
• Svenson S, Tomalia DA. 2012. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 64:102–115.
   Web of Science ®Google Scholar
• Swami A, Shi J, Gadde S, Votruba AR, Kolishetti N, Farokhzad OC. 2012. Nanoparticles for targeted and temporally controlled drug delivery. In: Multifunctional Nanoparticles for Drug Delivery Applications. Springer, pp. 9–29.
   PubMedGoogle Scholar
• Tassew NG, Charish J, Chestopalova L, Monnier PP. 2009. Sustained in vivo inhibition of protein domains using single-chain Fv recombinant antibodies and its application to dissect RGMa activity on axonal outgrowth. The Journal of Neuroscience, 29, 1126–1131.
   PubMed Web of Science ®Google Scholar
• Torchilin V. 2008. Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv.2008. 5:1003–1025.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145–160.
   PubMed Web of Science ®Google Scholar
• Veiseh O, Gunn JW, Zhang M. 2010. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 62:284–304.
   PubMed Web of Science ®Google Scholar
• Visaria R, Bischof JC, Loren M, Williams B, Ebbini E, Paciotti G, et al. 2007. Nanotherapeutics for enhancing thermal therapy of cancer. International Journal of Hyperthermia, 23, 501–511.
   PubMed Web of Science ®Google Scholar
• Wan L, Zhu S, Zhu J, Yang H, Li S, Li Y, et al. 2013. Production and characterization of a CD25-specific scFv-Fc antibody secreted from Pichia pastoris. Appl Microbiol Biotechnol. 97:3855–3863.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR, Farokhzad OC. 2008. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther.2008. 8:1063–1070.
   PubMed Web of Science ®Google Scholar
• Weinberg WC, Frazier-Jessen MR, Wu WJ, Weir A, Hartsough M, Keegan P, Fuchs C. 2005. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev. 24:569–584.
   PubMed Web of Science ®Google Scholar
• Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. 2012. Nanoparticles as drug delivery systems. Pharmacol Rep. 64:1020–1037.
   PubMed Web of Science ®Google Scholar
• Wissing S, Kayser O, Müller R. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 56:1257–1272.
   PubMed Web of Science ®Google Scholar
• Xiangbao Y, Linquan W, Mingwen H, Fan Z, Kai W, Xin Y, et al. 2014. Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity. Biomed Pharmacother. 68: 597–602.
   PubMed Web of Science ®Google Scholar
• Yang J, Huang X, Luo F, Cheng X, Cheng L, Liu B, Chen L, Hu R, Shi C, Zhuang G. 2014. Preparation and functional studies of hydroxyethyl chitosan nanoparticles loaded with anti-human death receptor 5 single-chain antibody. OncoTargets Ther. 7:779.
   PubMed Web of Science ®Google Scholar
• Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, et al. 2009. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small. 5: 235–243.
   PubMed Web of Science ®Google Scholar
• Yatvin M, Kreutz W, Horwitz B, Shinitzky M. 1980. pH-sensitive liposomes. possible clinical implications. Science. 210:1253–1255.
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Kumar A, Palakurthi S. 2009. Surface modified poly (amido) amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opin Drug Deliv.2009. 6:835–850.
   PubMed Web of Science ®Google Scholar
• Yockman JW, Maheshwari A, Han S-O, Kim SW. 2003. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J Control Release. 87:177–186.
   PubMed Web of Science ®Google Scholar
• Zhang B, Chen Q, Tang H, Xie Q, Ma M, Tan L, et al. 2010. Characterization of and biomolecule immobilization on the biocompatible multi-walled carbon nanotubes generated by functionalization with polyamidoamine dendrimers. Colloids Surf B Biointerfaces. 80:18–25.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. 2007. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 371:934–947.
   PubMed Web of Science ®Google Scholar